Questions on new Alzheimer's drug benefit, price loom large at ICER meeting
Bio Pharma Dive
JULY 16, 2021
"Right now, and I think for a while, the access is going to be pretty limited," former CMS and FDA head Mark McClellan said at the meeting, which featured yet another rebuke by experts of Aduhelm.
Let's personalize your content